Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology

Do I Need a Neuromuscular Specialist for Myasthenia Gravis?

At a Glance

While general neurologists can manage mild myasthenia gravis, neuromuscular specialists offer access to advanced biologics, multidisciplinary teams, and expert crisis management. Many patients benefit from a co-management approach, seeing a specialist annually while keeping their local doctor.

While a general neurologist is capable of diagnosing and managing mild or well-controlled myasthenia gravis (MG), seeing a neuromuscular specialist—particularly at a “high-volume” center—often provides significant advantages. MG care has become highly complex, requiring access to newer targeted treatments, coordinated care teams, and expert crisis management. For many patients, the travel and wait times to see a specialist are worth it to ensure they are receiving the most advanced and comprehensive care available.

The Goal: Minimal Symptom Expression

Many patients on standard treatments like prednisone or Mestinon continue to experience daily fatigue or intermittent double vision, assuming this is “as good as it gets.” However, the consensus goal of modern MG treatment is to achieve Minimal Symptom Expression (MSE) or remission [1][2]. This means you should have no symptoms that meaningfully interfere with your daily life [3].

If you are experiencing persistent daily symptoms despite standard therapy, a specialist can evaluate whether your current treatment is truly adequate or if it is time to escalate your care.

The Complexity of Modern Treatments

In recent years, the landscape of MG treatment has expanded dramatically. Modern management increasingly includes new, targeted biologic therapies such as efgartigimod, eculizumab, rozanolixizumab, ravulizumab, and zilucoplan [4][5][6].

These medications are highly effective for many, but prescribing them requires nuanced expertise. First, they are targeted based on your specific antibody status (e.g., whether you test positive for AChR or MuSK antibodies) because certain drugs only work for specific types of MG [7][2]. Second, like all powerful medications, they carry risks. Because these biologics suppress specific parts of your immune system, they can increase your risk of infections; for instance, some require mandatory vaccinations against meningitis before you can even start them [5][8]. Neuromuscular specialists are typically more experienced in balancing these risks against the benefits, navigating complex insurance approvals, and monitoring your immune health over time.

Surgical options also require specialized coordination. For patients undergoing a thymectomy (surgical removal of the thymus gland), careful perioperative management is critical. The established standard of care to prepare for surgery usually involves Intravenous Immunoglobulin (IVIG) or Plasmapheresis (PLEX), rapid-acting therapies used to optimize a patient’s strength and prevent postoperative complications [9][10]. Specialists are also increasingly using newer biologics alongside these standard treatments to help patients safely complete the procedure without experiencing postoperative respiratory failure [11].

Managing Crises and Emergencies

While many patients will never experience one, it is important to be prepared for a myasthenic crisis—a life-threatening complication where the muscles that control breathing become too weak to function, often requiring a ventilator.

The established, rapid-acting treatments used to reverse a crisis are IVIG and PLEX [12][13]. Research shows that expert care in specialized settings facilitates the reversal of myasthenic crises, with very low rates of extubation failure (the inability to successfully remove the breathing tube) [14]. Specialized centers often utilize standardized protocols for breathing trials that improve a patient’s chances of breathing on their own without prolonging their time on a ventilator [15]. Alongside standard IVIG and PLEX, specialists at high-volume centers are increasingly exploring the use of newer biologic therapies as an additional tool during severe crises to speed up the weaning process from mechanical ventilation [16][17].

The Power of Multidisciplinary Care Teams

Because MG can impact multiple systems in your body—affecting your ability to swallow, speak, breathe, and move—it requires a holistic, team-based approach [18][19].

Patients treated outside of specialized centers frequently report fragmented care due to a lack of clear referral pathways to allied health services, such as physical therapy, speech therapy, and pulmonology [20]. High-volume neuromuscular centers address this by utilizing multidisciplinary teams (MDTs). These teams improve medical decision-making, enhance patient safety, and accelerate access to appropriate treatments [21][22]. This coordinated care is especially critical during complex life events. For example, if an MG patient becomes pregnant, an MDT—involving neurologists, obstetricians, anesthesiologists, and pediatricians—provides essential supportive counseling, treatment planning, and close monitoring that improves pregnancy outcomes [23][24].

Finding the Right Balance

You do not necessarily have to choose one over the other. A common and highly effective strategy is the “co-management” model. You might travel to a specialized neuromuscular center once or twice a year to establish your overall treatment plan, while continuing to see your local general neurologist for routine follow-ups. You can locate specialized centers through resources like the Myasthenia Gravis Foundation of America (MGFA) clinic locator.

To suggest this to your current doctor without damaging your relationship, you might say: “I appreciate all the care you’ve provided. Given how complex MG can be, I was thinking it might be helpful for us to partner with an MG specialist at a high-volume center for an annual review of my treatment plan. What are your thoughts on a co-management approach?”

Common questions in this guide

When should I see a neuromuscular specialist for myasthenia gravis?
You should consider seeing a neuromuscular specialist if you experience persistent daily symptoms like fatigue or double vision despite standard therapy. Specialists have access to newer targeted treatments and multidisciplinary care teams to help you achieve minimal symptom expression.
Can I see both a general neurologist and a neuromuscular specialist for myasthenia gravis?
Yes, many patients use a highly effective co-management approach. You can travel to a specialized neuromuscular center once or twice a year to establish your overall treatment plan, while continuing to see your local general neurologist for routine follow-ups.
What is the treatment goal for myasthenia gravis?
The consensus goal of modern treatment is to achieve minimal symptom expression or remission. This means you should have no symptoms that meaningfully interfere with your daily life, activities, or relationships.
How is a myasthenic crisis treated in the hospital?
During a crisis, hospitals use rapid-acting treatments like Intravenous Immunoglobulin (IVIG) and plasmapheresis to reverse life-threatening breathing weakness. Specialized centers often use standardized protocols and may explore newer biologics to help patients breathe on their own sooner.
Are newer biologic treatments for myasthenia gravis right for everyone?
Newer biologic therapies are targeted based on your specific antibody status, such as testing positive for AChR or MuSK antibodies. Because they suppress parts of the immune system, they carry risks like increased infection and require expert monitoring by a specialist.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current symptom levels, do you feel we have achieved the goal of minimal symptom expression?
  2. 2.What is your experience navigating the insurance approval process for newer MG biologics?
  3. 3.Would you be open to a co-management approach where I consult with a neuromuscular specialist annually while continuing my routine care with you?
  4. 4.If I were to experience a myasthenic crisis, what is the protocol at the hospital you are affiliated with?
  5. 5.Do you have an established network of specialists, such as pulmonologists and speech therapists, that you coordinate with for MG care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Developing treatment guidelines for myasthenia gravis.

    Sanders DB, Wolfe GI, Narayanaswami P,

    Annals of the New York Academy of Sciences 2018; (1412(1)):95-101 doi:10.1111/nyas.13537.

    PMID: 29381223
  2. 2

    International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.

    Narayanaswami P, Sanders DB, Wolfe G, et al.

    Neurology 2021; (96(3)):114-122 doi:10.1212/WNL.0000000000011124.

    PMID: 33144515
  3. 3

    Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis.

    Chayanopparat S, Banyatcharoen P, Jitprapaikulsan J, et al.

    Scientific reports 2025; (15(1)):7219 doi:10.1038/s41598-025-90937-w.

    PMID: 40021769
  4. 4

    Targeted Treatments for Myasthenia Gravis in Children and Adolescents.

    Ramdas S, Painho T, Vanegas MI, et al.

    Paediatric drugs 2024; (26(6)):719-740 doi:10.1007/s40272-024-00649-3.

    PMID: 39198371
  5. 5

    The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis.

    Martinez Salazar A, Mokhtari S, Peguero E, Jaffer M

    Cells 2025; (14(10)) doi:10.3390/cells14100739.

    PMID: 40422242
  6. 6

    Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.

    Dalakas MC

    Current opinion in neurology 2020; (33(5)):545-552 doi:10.1097/WCO.0000000000000858.

    PMID: 32833750
  7. 7

    Autoimmune Myasthenia Gravis.

    Juel VC

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1270-1302 doi:10.1212/cont.0000000000001612.

    PMID: 41037173
  8. 8

    Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.

    Briani C, Visentin A

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):874-884 doi:10.1007/s13311-022-01222-x.

    PMID: 35349079
  9. 9

    A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.

    Alipour-Faz A, Shojaei M, Peyvandi H, et al.

    Acta neurologica Belgica 2017; (117(1)):245-249 doi:10.1007/s13760-016-0689-z.

    PMID: 27530310
  10. 10

    A case of thymoma in myasthenia gravis: Successful outcome after thymectomy.

    Dahal S, Bhandari N, Dhakal P, et al.

    International journal of surgery case reports 2019; (65()):229-232 doi:10.1016/j.ijscr.2019.10.069.

    PMID: 31734473
  11. 11

    Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report.

    Ren L, Wei L, Jiang S, et al.

    Frontiers in immunology 2025; (16()):1627584 doi:10.3389/fimmu.2025.1627584.

    PMID: 41112289
  12. 12

    SOP myasthenic crisis.

    Stetefeld H, Schroeter M

    Neurological research and practice 2019; (1()):19 doi:10.1186/s42466-019-0023-3.

    PMID: 33324885
  13. 13

    Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.

    Tavee J, Brannagan TH, Lenihan MW, et al.

    Muscle & nerve 2023; (68(4)):356-374 doi:10.1002/mus.27922.

    PMID: 37432872
  14. 14

    Weaning from mechanical ventilation in myasthenic crisis according to WEAN safe: most patients experience intermediate or prolonged weaning with no differences between early and late-onset compared to very-late onset myasthenia Gravis.

    Marois C, Combes A, Bouguerra M, et al.

    Annals of intensive care 2025; (15(1)):95 doi:10.1186/s13613-025-01515-2.

    PMID: 40658304
  15. 15

    Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study.

    Mazeraud A, Sivanandamoorthy S, Mancusi R, et al.

    Scientific reports 2024; (14(1)):19523 doi:10.1038/s41598-024-70373-y.

    PMID: 39174610
  16. 16

    Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.

    Song J, Wang H, Huan X, et al.

    Frontiers in immunology 2024; (15()):1418503 doi:10.3389/fimmu.2024.1418503.

    PMID: 39136012
  17. 17

    Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod.

    Watanabe K, Ohashi S, Watanabe T, et al.

    Frontiers in neurology 2024; (15()):1321058 doi:10.3389/fneur.2024.1321058.

    PMID: 38318438
  18. 18

    The Spectrum of Autonomic Dysfunction in Myasthenic Crisis.

    Benjamin RN, Aaron S, Sivadasan A, et al.

    Annals of Indian Academy of Neurology 2018; (21(1)):42-48 doi:10.4103/aian.AIAN_270_17.

    PMID: 29720797
  19. 19

    Infectious Thoracoabdominal Aortic Aneurysm Repair in a Patient with Myasthenia Gravis: A Case Report.

    Chiba K, Kinebuchi S, Komagamine M, et al.

    Annals of vascular diseases 2024; (17(4)):429-432 doi:10.3400/avd.cr.24-00099.

    PMID: 39726540
  20. 20

    Fragmented care and missed opportunities: the experiences of adults with myasthenia gravis in accessing and receiving allied health care in Australia.

    Devlin I, Williams KL, Shrubsole K

    Disability and rehabilitation 2023; (45(15)):2488-2496 doi:10.1080/09638288.2022.2094481.

    PMID: 35786287
  21. 21

    Significance of Multidisciplinary Teams for Patients with Oral and Maxillofacial Surgical Diseases: An Observational Retrospective Study in a General Hospital in China.

    Chen J, Yao Q, Wang X, et al.

    Journal of multidisciplinary healthcare 2024; (17()):6187-6198 doi:10.2147/JMDH.S504720.

    PMID: 39759085
  22. 22

    ESR Bridges: renal cell carcinoma-a multidisciplinary view.

    Mirón Mombiela R, Thomsen FF, Fuglø D, et al.

    European radiology 2025; (35(6)):3107-3109 doi:10.1007/s00330-024-11270-w.

    PMID: 39661148
  23. 23

    Fetal Surveillance in Pregnancies with Myasthenia Gravis.

    Cimpoca-Raptis BA, Ciobanu AM, Gica N, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(11)) doi:10.3390/medicina57111277.

    PMID: 34833495
  24. 24

    An Update: Myasthenia Gravis and Pregnancy.

    Hamel J, Ciafaloni E

    Neurologic clinics 2018; (36(2)):355-365 doi:10.1016/j.ncl.2018.01.005.

    PMID: 29655454

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider when making decisions about your myasthenia gravis care team and treatment plan.

Get notified when new evidence is published on Myasthenia gravis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.